TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call with Analysts / Investor on Financial Results for the quarter and nine months ended 31st December, 202307-02-2024
07-02-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201506-02-2024
Torrent Pharma Q3 Results Review - Strong Performance Across Branded Markets: Nirmal Bang
Domestic revenue grew by 12% YoY to Rs 14.15 billion.06-02-2024
Torrent Pharma Q3 Results Review - India, Latin America Drive Earnings: Motilal Oswal
Profitability remains on uptrend05-02-2024
Torrent Pharmaceuticals Q3 FY24 Results Live: Profit Rises by 56.54% YoY
Revenue increased by 9.67% YoY & profit increased by 56.54% YoY04-02-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meets under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201503-02-2024
Torrent Pharma Q3 PAT Jumps 52% To Rs 443 Crore
The drug firm had reported a net profit of Rs 292 crore in the October-December period of the last fiscal.02-02-2024
Q3FY24 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q3FY24 results: Financial Performance for Q3FY24: Revenue: Rs 2,732 crore, indicating a 10% increase. Gross Margin: 75%, maintaining a stable position in the market. Operational EBITDA: Rs 869 crore, experiencing a 20% growth. Exceptional Items: Gained net proceeds of Rs 88 crore from the sale of a US facility. Net Profit After Tax (PAT): Rs 443 crore, marking a significant 52% surge. Research & Development (R&D;) Spend: Rs 127 crore, reaffirming the company's commitment to innovation. Debt Equity Ratio: A ratio of 0.53, indicating a moderate level of debt in comparison to equity. Debt Service Coverage Ratio: At 2.21, suggesting the company's ability to service its debt is well-managed. Interest Service Coverage Ratio: Standing at 9.08, showing a strong ability to meet interest expenses. Net Profit Margin: The net profit margin stood at 16%, representing the profitability from the revenue earned. Country-wise Performance for Q3FY24: India: Revenues reached Rs 1,415 crore, up by 12%, outperforming the market in focus therapies. Brazil: Reported revenues of Rs 312 crore, growing by 26%, with constant currency revenues up by 17%. Germany: Achieved revenues of Rs 270 crore, increasing by 12%, with constant currency revenues rising by 6% due to tender wins. United States: US business revenues saw a slight decrease of 6% to Rs 274 crore, with constant currency revenues down by 7%, affected by a lack of new product launches. Result PDF02-02-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Date of payment of Dividend
Date of payment of dividend02-02-2024